Nexium (Esomeprazole)

Esomeprazole blocks the gastric H+/K+ ATPase enzyme, also known as the proton pump, on the surface of parietal cells. This inhibition stops the final step of acid secretion, leading to a sustained reduction in gastric acid output and an increase in stomach pH.

The prescribed dose of Nexium is determined by the treating physician based on the specific indication, severity of disease, patient age, renal and hepatic function, and any concomitant medications. Dosage adjustments are made individually to achieve optimal therapeutic effect.

Safety data for esomeprazole in pregnancy and lactation are limited. It should only be used when the potential benefit to the mother outweighs any possible risk to the fetus or infant, and the decision should be made by a qualified healthcare professional.

To place an order, submit an enquiry on the Nexium product page at gnhindia.com, specifying the required quantity. GNH India works with hospitals, pharmacies and procurement teams worldwide, verifies trade or institutional credentials, and then provides pricing, availability, shipping details and any necessary import documentation.

Esomeprazole is the S‑enantiomer of omeprazole and provides more consistent acid suppression with a slightly longer duration of action. Clinical studies suggest comparable efficacy to other PPIs, but individual response and drug‑interaction profiles may differ, making selection patient‑specific.

Nexium intravenous solution should be stored below 25 °C (77 °F) in its original packaging, protected from light and moisture. Do not freeze the product, and keep it out of reach of children.

Nexium is given as an intravenous infusion by a qualified healthcare professional. The solution is typically diluted in a compatible IV fluid and administered over a specified period, following the prescribing information and institutional protocols.

Serious risks include Clostridioides difficile‑associated diarrhea, severe allergic reactions such as anaphylaxis, Stevens‑Johnson syndrome, liver enzyme elevations, hypomagnesemia, and acute interstitial nephritis. Patients should be monitored for these events, especially during prolonged therapy.

Nexium is contraindicated in patients with known hypersensitivity to esomeprazole or any component of the formulation. Caution is advised for individuals with severe hepatic impairment, and it should be avoided in patients where alternative acid‑reducing therapy is more appropriate based on clinical judgment.